Vaidya Sane Ayurved Laboratories Limited (NSE:MADHAVBAUG)

India flag India · Delayed Price · Currency is INR
160.00
-15.00 (-8.57%)
Mar 30, 2026, 3:24 PM IST
Market Cap1.84B +43.5%
Revenue (ttm)979.90M +8.8%
Net Income82.09M +102.6%
EPS7.76 +229.3%
Shares Out10.52M
PE Ratio22.55
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume41,200
Average Volume7,000
Open173.00
Previous Close175.00
Day's Range159.95 - 173.00
52-Week Range90.00 - 335.00
Beta-0.02
RSI24.88
Earnings DateMay 22, 2026

About NSE:MADHAVBAUG

Vaidya Sane Ayurved Laboratories Limited, together with its subsidiaries, engages in the research, development, and sale of ayurvedic medicines and products in India. It operates through Sale of Product and Hospital Activity segments. The company sells medicines for arthritis and joint pains, cholesterol, diabetes, digestive, acidity, gastric, dyslipidemia, fever, cough, cold, general tonic, heart disease, hypertension/high blood pressure, liver, low glycemic index atta, obesity/weight management, piles and renal, skin, and wounds; and diet box... [Read more]

Sector Healthcare
Founded 1999
Employees 636
Stock Exchange National Stock Exchange of India
Ticker Symbol MADHAVBAUG
Full Company Profile

Financial Performance

In fiscal year 2025, NSE:MADHAVBAUG's revenue was 898.47 million, a decrease of -9.55% compared to the previous year's 993.31 million. Earnings were 71.36 million, an increase of 260.34%.

Financial Statements